Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Artemis Therapeutics, Inc. | exhibit_99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 14, 2012 (March 13, 2012)
INKSURE TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
000-24431
|
84-1417774
|
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
589 Fifth Avenue, Suite 401, New York, NY
|
10017
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(646) 233-1454
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On March 13, 2012 the registrant issued a press release announcing its 2011 Fiscal Year Financial Results. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
|
EXHIBIT NO.:
|
EXHIBIT DESCRIPTION:
|
|
99.1
|
Press Release dated March 13, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INKSURE TECHNOLOGIES, INC.
|
|
Date: March 14, 2012
|
|
By: /s/ Tal Gilat
|
|
Name: Tal Gilat
|
|
Title: President and Chief Executive Officer
|